O	0	4	Does
O	5	6	a
B-intervention	7	18	homeopathic
I-intervention	19	27	medicine
O	28	34	reduce
B-condition	35	38	hot
I-condition	39	46	flushes
O	47	54	induced
O	55	57	by
O	58	66	adjuvant
O	67	76	endocrine
O	77	84	therapy
O	85	87	in
O	88	97	localized
O	98	104	breast
O	105	111	cancer
O	112	120	patients
O	120	121	?

O	122	123	A
O	124	135	multicenter
O	136	146	randomized
O	147	154	placebo
O	154	155	-
O	155	165	controlled
O	166	171	phase
O	172	175	III
O	176	181	trial
O	181	182	.

O	183	192	Endocrine
O	193	200	therapy
O	201	202	(
O	202	204	ET
O	204	205	)
O	206	210	used
O	211	213	to
O	214	220	reduce
O	221	224	the
O	225	229	risk
O	230	232	of
O	233	243	recurrence
O	244	246	in
O	247	254	hormone
O	255	263	receptor
O	263	264	-
O	264	274	expressing
O	275	282	disease
O	283	284	(
O	284	286	75
O	286	287	%
O	288	290	of
O	291	297	breast
O	298	305	cancers
O	305	306	)
O	307	309	is
O	310	320	associated
O	321	325	with
O	326	335	worsening
O	336	338	of
O	339	350	climacteric
O	351	359	symptoms
O	360	364	with
O	365	366	a
O	367	375	negative
O	376	382	impact
O	383	385	on
O	386	393	quality
O	394	396	of
O	397	401	life
O	402	403	(
O	403	406	QoL
O	406	407	)
O	407	408	.

O	409	419	Homeopathy
O	420	425	might
O	426	431	allow
O	432	433	a
O	434	440	better
O	441	451	management
O	452	454	of
O	455	458	hot
O	459	466	flushes
O	467	468	(
O	468	470	HF
O	470	471	)
O	471	472	.

O	473	475	In
O	476	480	this
O	481	492	multicenter
O	493	503	randomized
O	504	510	double
O	510	511	-
O	511	516	blind
O	517	524	placebo
O	524	525	-
O	525	535	controlled
O	536	541	phase
O	542	545	III
O	546	551	study
O	552	553	(
O	554	568	ClinicalTrials
O	568	569	.
O	569	572	gov
O	573	584	NCT01246427
O	584	585	)
O	585	586	,
O	587	589	we
O	590	598	enrolled
B-age	599	600	≥
I-age	601	603	18
I-age	604	609	years
O	610	613	old
B-eligibility	614	619	women
I-eligibility	620	624	with
I-eligibility	625	639	histologically
I-eligibility	640	646	proven
I-eligibility	647	650	non
I-eligibility	651	661	metastatic
I-eligibility	662	671	localized
I-eligibility	672	678	breast
I-eligibility	679	685	cancer
I-eligibility	685	686	,
I-eligibility	687	691	with
I-eligibility	692	699	Eastern
I-eligibility	700	711	Cooperative
I-eligibility	712	720	Oncology
I-eligibility	721	726	Group
I-eligibility	726	727	-
I-eligibility	727	738	Performance
I-eligibility	739	745	Status
I-eligibility	746	747	(
I-eligibility	747	751	ECOG
I-eligibility	751	752	-
I-eligibility	752	754	PS
I-eligibility	754	755	)
I-eligibility	756	757	≤
I-eligibility	758	759	1
I-eligibility	759	760	,
I-eligibility	761	768	treated
I-eligibility	769	772	for
I-eligibility	773	775	at
I-eligibility	776	781	least
I-eligibility	782	783	1
I-eligibility	784	789	month
I-eligibility	790	794	with
I-eligibility	795	803	adjuvant
I-eligibility	804	806	ET
I-eligibility	806	807	,
I-eligibility	808	811	and
I-eligibility	812	823	complaining
I-eligibility	824	829	about
I-eligibility	830	838	moderate
I-eligibility	839	841	to
I-eligibility	842	848	severe
I-eligibility	849	851	HF
O	851	852	.

O	853	861	Patients
O	862	868	should
O	869	872	not
O	873	875	be
O	876	885	scheduled
O	886	889	for
O	890	902	chemotherapy
O	903	905	or
O	906	918	radiotherapy
O	918	919	,
O	920	923	and
O	924	927	had
O	928	930	no
O	931	941	associated
O	942	951	pathology
O	952	957	known
O	958	960	to
O	961	967	induce
O	968	970	HF
O	970	971	.

O	972	977	After
O	978	979	a
O	980	981	2
O	981	982	-
O	983	985	to
O	986	987	4
O	987	988	-
O	988	992	week
O	993	1000	placebo
O	1001	1015	administration
O	1015	1016	,
O	1017	1019	we
O	1020	1028	randomly
O	1029	1037	assigned
O	1038	1039	(
O	1039	1040	1
O	1040	1041	:
O	1041	1042	1
O	1042	1043	)
O	1044	1052	patients
O	1053	1057	with
O	1058	1061	HFS
O	1062	1063	≥
O	1064	1066	10
O	1067	1072	using
O	1073	1075	an
O	1076	1087	interactive
O	1088	1091	web
O	1091	1092	-
O	1092	1097	based
O	1098	1109	centralized
O	1110	1118	platform
O	1119	1121	to
O	1122	1125	BRN
O	1125	1126	-
O	1126	1128	01
O	1129	1140	homeopathic
O	1141	1149	medicine
O	1150	1157	complex
O	1158	1159	(
O	1159	1167	Actheane
O	1167	1168	®
O	1168	1169	)
O	1170	1172	in
O	1173	1176	arm
O	1177	1178	A
O	1179	1181	or
B-control	1182	1189	Placebo
I-control	1190	1191	(
I-control	1191	1194	Arm
I-control	1195	1196	P
I-control	1196	1197	)
O	1197	1198	.

O	1199	1212	Randomization
O	1213	1216	was
O	1217	1227	stratified
O	1228	1230	by
O	1231	1239	adjuvant
O	1240	1242	ET
O	1243	1244	(
O	1244	1253	taxoxifen
O	1253	1254	/
O	1254	1263	aromatase
O	1264	1273	inhibitor
O	1273	1274	)
O	1275	1278	and
O	1279	1289	recruiting
O	1290	1294	site
O	1294	1295	.

O	1296	1298	HF
O	1299	1305	scores
O	1306	1307	(
O	1307	1310	HFS
O	1310	1311	)
O	1312	1316	were
O	1317	1327	calculated
O	1328	1330	as
O	1331	1334	the
O	1335	1339	mean
O	1340	1342	of
O	1343	1345	HF
O	1346	1357	frequencies
O	1358	1364	before
O	1365	1378	randomization
O	1378	1379	,
O	1380	1382	at
O	1383	1384	4
O	1384	1385	,
O	1386	1389	and
O	1390	1392	at
O	1393	1394	8
O	1395	1400	weeks
O	1401	1405	post
O	1405	1406	-
O	1406	1419	randomization
O	1420	1421	(
O	1421	1424	pre
O	1424	1425	-
O	1425	1426	,
O	1427	1429	4w
O	1429	1430	,
O	1430	1431	-
O	1432	1435	and
O	1436	1438	8w
O	1438	1439	-
O	1439	1440	)
O	1441	1449	weighted
O	1450	1452	by
O	1453	1454	a
O	1455	1456	4
O	1456	1457	-
O	1457	1462	level
O	1463	1472	intensity
O	1473	1478	scale
O	1478	1479	.

O	1480	1487	Primary
O	1488	1496	endpoint
O	1497	1500	was
O	1501	1509	assessed
O	1510	1512	at
O	1513	1514	4
O	1514	1515	-
O	1515	1519	week
O	1520	1524	post
O	1524	1525	-
O	1525	1538	randomization
O	1538	1539	,
O	1540	1542	as
O	1543	1546	the
B-outcome-Measure	1547	1556	variation
I-outcome-Measure	1557	1564	between
I-outcome-Measure	1565	1568	pre
I-outcome-Measure	1568	1569	-
I-outcome-Measure	1570	1573	and
I-outcome-Measure	1574	1576	4w
I-outcome-Measure	1576	1577	-
I-outcome-Measure	1577	1580	HFS
O	1580	1581	.

O	1582	1591	Secondary
O	1592	1601	endpoints
O	1602	1610	included
B-outcome-Measure	1611	1614	HFS
I-outcome-Measure	1615	1624	variation
I-outcome-Measure	1625	1632	between
I-outcome-Measure	1633	1636	pre
I-outcome-Measure	1636	1637	-
I-outcome-Measure	1638	1641	and
I-outcome-Measure	1642	1644	8w
I-outcome-Measure	1644	1645	-
I-outcome-Measure	1645	1648	HFS
O	1648	1649	,
B-outcome-Measure	1650	1660	compliance
I-outcome-Measure	1661	1664	and
I-outcome-Measure	1665	1674	tolerance
I-outcome-Measure	1675	1683	assessed
I-outcome-Measure	1684	1685	8
I-outcome-Measure	1686	1691	weeks
I-outcome-Measure	1692	1697	after
I-outcome-Measure	1698	1711	randomization
O	1711	1712	,
O	1713	1716	and
B-outcome-Measure	1717	1720	QoL
O	1721	1724	and
B-outcome-Measure	1725	1737	satisfaction
O	1738	1746	assessed
O	1747	1749	at
O	1750	1751	4
O	1751	1752	-
O	1753	1756	and
O	1757	1758	8
O	1758	1759	-
O	1759	1763	week
O	1764	1768	post
O	1768	1769	-
O	1769	1782	randomization
O	1782	1783	.

B-total-participants	1784	1787	Two
I-total-participants	1788	1795	hundred
I-total-participants	1796	1802	ninety
I-total-participants	1802	1803	-
I-total-participants	1803	1807	nine
O	1808	1816	patients
O	1817	1821	were
O	1822	1830	included
O	1830	1831	,
O	1832	1835	and
B-total-participants	1836	1839	138
O	1840	1841	(
O	1841	1843	46
O	1843	1844	.
O	1844	1845	2
O	1845	1846	%
O	1846	1847	)
O	1848	1858	randomized
O	1859	1860	(
O	1860	1861	A
O	1861	1862	,
B-intervention-participants	1863	1865	65
O	1865	1866	;
O	1867	1868	P
O	1868	1869	,
B-control-participants	1870	1872	73
O	1872	1873	)
O	1873	1874	.

B-outcome	1875	1881	Median
I-outcome	1882	1884	4w
I-outcome	1884	1885	-
I-outcome	1885	1888	HFS
I-outcome	1889	1897	absolute
I-outcome	1898	1907	variation
O	1908	1909	(
O	1909	1910	A
O	1910	1911	,
B-iv-cont-median	1912	1913	-
I-iv-cont-median	1914	1915	2
I-iv-cont-median	1915	1916	.
I-iv-cont-median	1916	1917	9
O	1917	1918	;
O	1919	1920	P
O	1920	1921	,
B-cv-cont-median	1922	1923	-
I-cv-cont-median	1924	1925	2
I-cv-cont-median	1925	1926	.
I-cv-cont-median	1926	1927	5
I-cv-cont-median	1928	1934	points
O	1934	1935	,
O	1936	1937	p
O	1938	1939	=
O	1940	1941	0
O	1941	1942	.
O	1942	1945	756
O	1945	1946	)
O	1947	1950	and
B-outcome	1951	1959	relative
I-outcome	1960	1968	decrease
O	1969	1970	(
O	1970	1971	A
O	1971	1972	,
O	1973	1974	-
O	1975	1977	17
O	1977	1978	%
O	1978	1979	;
O	1980	1981	P
O	1981	1982	,
O	1983	1984	-
O	1985	1987	15
O	1987	1988	%
O	1988	1989	,
O	1990	1991	p
O	1992	1993	=
O	1994	1995	0
O	1995	1996	.
O	1996	1999	629
O	1999	2000	)
O	2001	2005	were
O	2006	2009	not
O	2010	2023	statistically
O	2024	2033	different
O	2033	2034	.

O	2035	2042	However
O	2042	2043	,
B-outcome	2044	2046	4w
I-outcome	2046	2047	-
I-outcome	2047	2050	HFS
I-outcome	2051	2060	decreased
O	2061	2064	for
B-iv-bin-abs	2065	2067	46
O	2068	2069	(
B-iv-bin-percent	2069	2071	75
I-iv-bin-percent	2071	2072	%
O	2072	2073	)
O	2074	2076	in
O	2077	2078	A
O	2079	2081	vs
B-cv-bin-abs	2082	2084	48
O	2085	2086	(
B-cv-bin-percent	2086	2088	68
I-cv-bin-percent	2088	2089	%
O	2089	2090	)
O	2091	2099	patients
O	2100	2102	in
O	2103	2104	P
O	2105	2108	arm
O	2108	2109	.

B-outcome	2110	2112	4w
I-outcome	2112	2113	-
I-outcome	2113	2116	QoL
O	2117	2120	was
O	2121	2127	stable
O	2128	2130	or
O	2131	2139	improved
O	2140	2143	for
O	2144	2156	respectively
B-iv-bin-abs	2157	2159	43
O	2160	2161	(
B-iv-bin-percent	2161	2163	72
I-iv-bin-percent	2163	2164	%
O	2164	2165	)
O	2166	2168	vs
B-cv-bin-abs	2169	2171	51
O	2172	2173	(
B-cv-bin-percent	2173	2175	74
I-cv-bin-percent	2175	2176	%
O	2176	2177	)
O	2178	2186	patients
O	2187	2188	(
O	2188	2189	p
O	2190	2191	=
O	2192	2193	0
O	2193	2194	.
O	2194	2197	470
O	2197	2198	)
O	2198	2199	.

O	2200	2203	The
O	2204	2212	efficacy
O	2213	2221	endpoint
O	2222	2225	was
O	2226	2229	not
O	2230	2237	reached
O	2237	2238	,
O	2239	2242	and
O	2243	2246	BRN
O	2246	2247	-
O	2247	2249	01
O	2250	2264	administration
O	2265	2268	was
O	2269	2272	not
O	2273	2285	demonstrated
O	2286	2288	as
O	2289	2291	an
O	2292	2301	efficient
O	2302	2311	treatment
O	2312	2314	to
O	2315	2324	alleviate
O	2325	2327	HF
O	2328	2336	symptoms
O	2337	2340	due
O	2341	2343	to
O	2344	2352	adjuvant
O	2353	2355	ET
O	2356	2358	in
O	2359	2365	breast
O	2366	2372	cancer
O	2373	2381	patients
O	2381	2382	.

O	2383	2390	However
O	2390	2391	,
O	2392	2395	the
O	2396	2401	study
O	2402	2406	drug
O	2407	2421	administration
O	2422	2425	led
O	2426	2428	to
O	2429	2438	decreased
O	2439	2442	HFS
O	2443	2447	with
O	2448	2449	a
O	2450	2458	positive
O	2459	2465	impact
O	2466	2468	on
O	2469	2472	QoL
O	2472	2473	.

O	2474	2481	Without
O	2482	2485	any
O	2486	2497	recommended
O	2498	2507	treatment
O	2508	2510	to
O	2511	2516	treat
O	2517	2519	or
O	2520	2529	alleviate
O	2530	2533	the
O	2534	2536	HF
O	2536	2537	-
O	2537	2544	related
O	2545	2554	disabling
O	2555	2563	symptoms
O	2563	2564	,
O	2565	2573	Actheane
O	2573	2574	®
O	2575	2580	could
O	2581	2583	be
O	2584	2585	a
O	2586	2595	promising
O	2596	2602	option
O	2602	2603	,
O	2604	2613	providing
O	2614	2616	an
O	2617	2628	interesting
O	2629	2636	support
O	2637	2640	for
O	2641	2647	better
O	2648	2657	adherence
O	2658	2660	to
O	2661	2663	ET
O	2663	2664	,
O	2665	2672	thereby
O	2673	2681	reducing
O	2682	2685	the
O	2686	2690	risk
O	2691	2693	of
O	2694	2704	recurrence
O	2705	2709	with
O	2710	2711	a
O	2712	2716	good
O	2717	2726	tolerance
O	2727	2734	profile
O	2734	2735	.
